Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd., explained in plain language.
-
New drug candidate targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests an experimental drug called FDA018-ADC in people with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About…
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for tough breast cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug called FDA018-ADC against standard chemotherapy for people with advanced triple-negative breast cancer that has come back after taxane treatment. About 350 participants will be randomly assigned to receive either the new drug or a standard chemo chosen…
Phase: PHASE3 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC